

1ST INTERNATIONAL CONFERENCE ON

Ph+Leukemias



Bologna, Royal Hotel Carlton
September 29-30, 2025

September 29, 2025

1.30 pm Registration

2.15 pm Welcome and introduction

F. Castagnetti (Bologna), C. Papayannidis (Bologna), P.L. Zinzani (Bologna)

2.30 pm **SESSION I - BIOLOGY**

Chairmen: D. Cilloni (Turin), F. Pane (Naples)

2.30 pm Mutations in BCR::ABL1 and beyond *S. Soverini (Bologna)*

2.50 pm Is BCR::ABL1 the key target in all CML patients? *K. Machová Poláková (Prague, Czech Republic)*

3.10 pm Biology of Ph+ ALL: new insights for risk stratification *I. Iacobucci (Memphis, USA)*

3.30 pm Beyond the Ph+ cell: the role of microenvironment *A. Curti (Bologna)*

3.50 pm Discussion

4.10 pm *Coffee break*

4.25 pm **SESSION II - FIRST LINE APPROACHES IN 2025**

Chairmen: M. Bocchia (Siena), F. Grimaldi (Naples)

4.25 pm ELN 2025 recommendations *D. Milojkovic (London, United Kingdom)*

4.45 pm New drugs in first-line CML treatment *M. Breccia (Rome)*

5.05 pm Chemo-free approach of Ph+ ALL *S. Chiaretti (Rome)*

5.25 pm How should we monitor MRD in Ph+ ALL: BCR-ABL or IgH/TCR? *R. Kim (Paris, France)*

5.45 pm Discussion

6.05 pm LECTURE I

Introduction: G. Rosti (Meldola-FC)

CML and Ph+ ALL: what's new @ MDACC *E.J. Jabbour (Houston, USA)*

September 30, 2025

08.30 am SESSION III - HOT TOPICS IN 2025

Chairmen: G. Binotto (Padova), D. Russo (Brescia)

08.30 am New challenges in treatment-free remission *F.E. Nicolini (Lyon, France)*

08.50 am Advanced phase CML *C. Fava (Turin)*

09.10 am Ph like ALL: diagnosis and treatment *G. Martinelli (Bologna)*

09.30 am Allo-SCT in Ph+ ALL: is it still necessary? *A. Rambaldi (Bergamo)*

09.50 am Discussion

10.10 am *Coffee break*

10.25 am SESSION IV: LATER LINES AND RELAPSED DISEASE

Chairmen: A. Candoni (Modena), F. Stagno (Messina)

10.25 am Second and third-line therapy in CML *J.V. Garcia Gutierrez (Madrid, Spain)*

10.45 am Treatment of CML patients with high cardiovascular risk *G. Caocci (Cagliari)*

11.05 am TKI based approach in R/R Ph+ ALL *M. Bonifacio (Verona)*

11.25 am Antibodies in R/R Ph+ ALL: present and future *C. Papayannidis (Bologna)*

11.45 am Discussion

12.05 pm SESSION V: FUTURE OF PH+ LEUKEMIAS TREATMENT

Chairmen: E. Abruzzese (Rome), M. Cerrano (Turin)

12.05 pm Novel agents for the treatment of CML *M. Tiribelli (Udine)*

12.25 pm New immunotherapy strategies in Ph+ ALL *F. Lussana (Milan)*

12.45 pm Discussion

1.00 pm LECTURE II

Introduction: A. Rambaldi (Bergamo)

CAR-T cells in ALL: present and pitfalls *C. Roddie (London, United Kingdom)*

1.30 pm Arrivederci and see you in 2027

1ST INTERNATIONAL CONFERENCE ON

Ph+ Leukemias



MEETING VENUE

Royal Hotel Carlton

Via Montebello, 8 - 40121 Bologna, Italy

Phone +39 051 249361

www.royalhotelcarltonbologna.com

REGISTRATION

Registration is free and available at

www.ercongressi.it in the section “I nostri congressi/2025”

OFFICIAL LANGUAGE

English. No simultaneous translation is provided.

CME

An Italian CME application has been submitted as follows:

- Provider Studio ER Congressi Srl - ID 828-454296
- N. 5,6 CME for *Physicians* (disciplines: hematology), *Pharmacists* (other sector pharmacists, SSN public pharmacists, territorial pharmacists), *Biologists*
- Educational Objective: linee guida-protocolli-procedure

SCIENTIFIC SECRETARIAT

Fausto Castagnetti

IRCCS Azienda Ospedaliero-Universitaria di Bologna

Istituto di Ematologia “Lorenzo e Ariosto Seràgnoli”

Dipartimento di Scienze Mediche e Chirurgiche

Università di Bologna

Via Massarenti, 9 - 40138 Bologna, Italy

Cristina Papayannidis

IRCCS Azienda Ospedaliero-Universitaria di Bologna

Istituto di Ematologia “Lorenzo e Ariosto Seràgnoli”

Dipartimento di Scienze Mediche e Chirurgiche

Università di Bologna

Via Massarenti, 9 - 40138 Bologna, Italy

ORGANIZING SECRETARIAT

Studio E.R. Congressi

Via De' Poeti 1/7 - 40124 Bologna, Italy

Phone +39 051 4210559

E-mail: ercongressi@ercongressi.it

www.ercongressi.it

1ST INTERNATIONAL CONFERENCE ON

Ph/Leukemias



Auspices

 **fondazione GIMEMA** onlus
per la promozione e lo sviluppo della ricerca scientifica
sulle malattie ematologiche. **FRANCO MANDELLI**



SIE
Società italiana
di ematologia



With an unrestricted educational grant of:

AMGEN



SOLVE
ON.

 **NOVARTIS**

 **Pfizer**
Oncology

 **GILEAD** |  **Kite**

AstraZeneca 